LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25

LIFECORE BIOMEDICAL, INC. DE

Financials through Q4 FY2025, quarter ended May 25, 2025Last filing: 10-Q on Aug 5, 2026

$6.39+0.01 (+0.16%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

LIFECORE BIOMEDICAL, INC. DE income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q4 2025 2025-05-25	Q3 2025 2025-02-23	Q2 2025 2024-11-24	Q1 2025 2024-08-25	Q4 2024 2024-05-26	Q3 2024 2024-02-25	Q2 2024 2023-11-26	Q1 2024 2023-08-27	Q4 2023 2023-05-28	Q3 2023 2023-02-26	Q2 2023 2022-11-27	Q1 2023 2022-08-28	Q4 2022 2022-05-29	Q3 2022 2022-02-27	Q2 2022 2021-11-28	Q1 2022 2021-08-29	Q4 2021 2021-05-30	Q3 2021 2021-02-28	Q2 2021 2020-11-29	Q1 2021 2020-08-30	Q4 2020 2020-05-31	Q3 2020 2020-02-23	Q2 2020 2019-11-24	Q1 2020 2019-08-25	Q4 2019 2019-05-26	Q3 2019 2019-02-24	Q2 2019 2018-11-25	Q1 2019 2018-08-26	Q4 2018 2018-05-27	Q3 2018 2018-02-25	Q2 2018 2017-11-26	Q1 2018 2017-08-27	Q4 2017 2017-05-28	Q3 2017 2017-02-26	Q2 2017 2016-11-27	Q1 2017 2016-08-28	Q4 2016 2016-05-29	Q3 2016 2016-02-28	Q2 2016 2015-11-29	Q1 2016 2015-08-30
Revenue	36	35	33	25	38	36	30	25	31	27	22	24	28	35	26	22	45	28	24	23	156	153	143	139	153	156	125	125	141	145	122	116	121	129	110	109	135	130	140	135
Cost of Revenue	22	25	21	19	21	24	20	22	23	18	16	18	14	24	14	17	30	17	13	17	132	133	127	123	127	134	108	108	116	125	108	97	49	113	117	111	53	117	123	117
Gross Profit	14	9.85	11	5.39	17	12	9.96	2.73	7.78	8.55	5.68	5.98	10	12	11	5.55	15	11	11	5.29	24	20	16	15	26	22	17	16	25	20	15	19	19	23	17	20	23	13	17	18
Research & Development	2.10	2.05	1.92	2.19	2.16	2.17	2.10	2.15	2.12	2.23	2.18	2.21	2.12	2.25	1.68	1.69	1.16	1.64	1.59	1.74	2.71	2.75	2.82	2.82	3.46	2.74	2.48	2.79	3.60	3.11	3.37	2.72	3.56	2.01	1.97	1.94	1.82	1.90	1.64	1.88
Selling, General & Admin	8.98	9.98	11	15	12	9.85	9.34	9.20	12	10	8.29	8.10	7.00	14	5.46	6.95	9.69	7.15	6.71	7.49	18	19	19	17	18	16	14	14	13	13	12	13	11	15	14	14	11	11	13	12
Operating Expenses	–	–	13	17	15	13	11	11	14	15	11	9.25	9.95	21	7.77	9.77	9.68	11	9.40	16	-11	35	22	20	24	18	17	17	17	16	16	16	14	19	16	16	12	47	14	14
Operating Income	5.33	-9.03	-1.96	-12	2.15	-0.90	-1.48	-8.61	-6.64	-6.53	-5.35	-3.27	-2.51	-9.64	3.69	-4.22	-6.63	0.07	1.37	-11	-0.45	-15	-6.04	-4.38	2.48	3.24	0.01	-0.26	8.07	3.49	-0.70	2.73	1.61	4.33	3.26	5.47	6.25	-34	2.81	3.94
Interest Expense	5.73	5.59	–	5.38	5.85	4.29	–	–	3.93	4.86	3.62	3.25	1.67	3.68	2.77	6.13	2.32	2.56	1.60	1.67	-1.81	2.21	2.17	2.08	–	1.77	–	–	–	–	–	–	–	–	–	0.65	0.56	0.48	0.44	0.50
Interest & Investment Income	0.21	0.11	–	0.02	–	–	–	–	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.03	0.02	0.01	0.01	0.01	-0.02	0.05	0.03	0.03	0.03	0.03	0.03	0.05	0.05	0.09	0.04	0.03	0.00	0.01	0.00	0.00	0.01	0.02	0.02	0.03
Other Non-Operating Income	0.17	0.33	-0.30	-0.20	-1.10	-0.81	-0.97	-0.17	-0.83	0.10	-0.24	-0.20	0.12	0.29	0.33	0.05	-11	0.31	-9.71	-1.52	-0.26	0.07	-0.01	0	0	0	0.60	1.00	0.70	0	1.30	0.90	0.20	0.70	–	–	0.20	0	0.20	0.80
Merger & Restructuring Charges	-2.52	-0.12	0.40	0.48	0.74	0.77	0.16	-0.01	-3.54	2.57	0.56	1.05	-7.53	5.27	0.63	1.13	5.47	2.07	1.10	6.67	-9.88	14	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	1.00	-1.00	–	–	46	0	32	–	0	0	0	–	1.44	11	–	–	2.00	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	–	-7.64	–	–	0.00	0	0	0	-0.04	0	0	2.11	-0.13	0	-0.01	-0.02	-0.02	-0.07	0.02	0.01	-0.01	-0.15	0.01	0.01	-0.21	0.03	0.00	0.00	-0.06	-0.14	0.04	0.00	-0.32	-0.21	-0.06	0.00	-0.07	–	–	0.00
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	0	-2.08	–	–	–	–	–	–
Pretax Income	-1.11	-15	-6.53	-16	-7.14	15	14	-13	-37	-11	-9.20	-6.70	-3.71	-7.53	1.27	-10	-20	-3.28	-9.92	-14	0.24	-17	-7.91	-6.15	0.97	1.92	0.31	0.44	8.70	3.45	0.58	3.67	1.82	5.05	2.07	5.23	6.31	-34	3.00	–
Income Tax Expense	0.03	-0.01	0.04	-0.03	-0.06	0.22	-0.07	0.09	0.23	0.07	0.00	0.00	0.38	3.39	-6.28	-1.81	-5.33	-1.53	-1.53	-3.79	-0.93	-5.31	-1.17	-1.37	0.60	0.39	0.42	0.11	1.99	-13	0.17	1.31	-0.10	1.56	0.69	1.89	2.05	-13	1.07	1.69
Income from Continuing Operations	-1.15	-15	-6.57	-16	-7.09	15	14	-13	-37	-11	-9.20	-6.71	-3.63	-11	7.55	-8.47	-0.78	-1.75	-8.39	-9.99	-15	-12	-6.74	-4.78	0.37	1.53	-0.11	0.34	6.71	16	0.41	2.36	2.60	3.59	0.77	3.18	–	–	–	–
Income from Discontinued Operations	0	0	0	0	0.00	0.85	-0.02	1.86	-2.29	-25	-3.61	-4.26	-52	-2.67	-46	-0.91	-2.09	-5.23	-3.23	-2.42	-16	0	0	0	-0.63	-0.47	-0.47	-0.15	-0.60	-0.20	0.10	-0.14	–	–	–	–	–	–	–	–
Net Income incl. Noncontrolling Interests	–	–	–	–	–	–	–	–	-39	-37	-13	-11	-55	-14	-38	-9.39	-1.28	-6.98	-12	-12	–	–	-6.74	-4.78	-0.26	1.07	-0.59	0.19	6.11	16	0.51	2.21	2.46	3.49	1.37	3.35	4.80	-21	1.93	2.99
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	–	–	0.00	0.00	0.03	0.07	0.01	-0.01	0.05	0.03	0.07	0.02	0.06	0.04
Net Income	-1.15	-15	-6.57	-16	-7.08	16	14	-11	-39	-37	-13	-11	-55	-14	-38	-9.39	-1.28	-6.98	-12	-12	-15	-12	-6.74	-4.78	-0.26	1.07	-0.58	0.19	6.11	16	0.49	2.15	2.45	3.50	1.33	3.31	4.73	-21	1.87	2.95
Preferred Dividends	0.85	0.84	–	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-2.05	-16	-8.70	-16	-7.08	16	14	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.06	-0.42	-0.25	-0.53	-0.23	0.51	0.47	-0.35	-1.32	-1.20	-0.43	-0.37	-1.88	-0.46	-1.31	-0.32	-0.04	-0.24	-0.40	-0.42	-0.52	-0.39	-0.23	-0.16	-0.01	0.03	-0.02	0.01	0.22	0.58	0.02	0.08	0.09	0.13	0.05	0.12	0.17	-0.78	0.07	0.11
EPS (Diluted)(per share)	-0.06	-0.42	-0.25	-0.53	-0.19	0.42	0.39	-0.35	-1.32	-1.20	-0.43	-0.37	-1.88	-0.46	-1.31	-0.32	-0.04	-0.24	-0.40	-0.42	-0.52	-0.39	-0.23	-0.16	-0.01	0.04	-0.02	0.01	0.22	0.57	0.02	0.08	0.09	0.13	0.05	0.12	0.17	-0.78	0.07	0.11
Shares Outstanding (Basic, Weighted)(shares)	37	37	34	31	31	30	30	30	30	30	30	30	29	29	29	29	29	29	29	29	29	29	29	29	29	29	28	28	28	28	28	28	27	27	27	27	27	27	27	27
Shares Outstanding (Diluted, Weighted)(shares)	37	37	34	31	37	37	36	30	30	30	30	30	29	29	29	29	29	29	29	29	29	29	29	29	29	29	28	28	28	28	28	28	28	28	28	28	27	27	27	27
EBITDA	7.24	-6.95	0.09	-9.59	4.16	1.11	0.50	-6.45	-3.97	-3.32	-2.41	1.08	1.00	-6.09	9.62	0.84	-1.57	5.06	6.10	-5.50	4.59	-10	-1.51	0.12	7.20	7.29	3.32	2.89	11	6.63	2.29	5.68	4.46	7.05	5.81	8.02	9.16	-31	4.94	6.15
Provision for Credit Losses	–	–	-0.14	-0.01	0.19	0.04	0.02	0.02	-0.04	0.20	0	0	0	-0.21	0.14	0.06	0.66	0.18	0.07	0.04	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 31.3%
Operating margin: -13.4%
Net margin: -30.0%
Return on equity, FY2025: -612.1%

Financial strength

Current ratio: 3.87
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 79.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –